3d rendering chromosomes
3d rendering chromosomes

Dividend Policy

3d rendering chromosomes
3d rendering chromosomes

International Biotechnology Trust offers investors a rare combination of capital growth and sustainable dividend income.

In September 2016, the Trust announced its intention to pay a dividend equivalent to 4% of the Trust's net asset value at the end of the preceding financial year, paid in two equal instalments at the end of January and August following that year-end.

Dividend payment date

Dividend amount
31 January 202314.0p per share
31 August 202215.7p per share
31 January 202215.7p per share
31 August 202114.2p per share
31 January 202114.2p per share
28 August 202012.4p per share
31 January 202012.4p per share
30 August 201914.0p per share
31 January 201914.0p per share
31 August 201813.5p per share
31 January 201813.5p per share
31 August 201711.5p per share
31 January 201711.5p per share

In the current environment of generally low and contracting income in the equity and debt markets, yield is attractive to investors, yet most yields are found in sectors where growth prospects are limited. By paying a dividend from capital reserves, the Trust is able to offer investors a dividend, while still investing in the biotech sector where the prospects for high growth remain for the foreseeable future.


The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).

I do not accept →